This website uses cookies in order to maximize its functionality and to provide you with better user experience.

Closing this window or continuing to navigate in the website means that you understand and accept the use of cookies in the website.

Roche Navigation Menu Roche4Med : Roche4Med

Sign in
Logout
Search

Roche

Up
Home
Search
Close search

Searching

Home
Products
Congresses & Events
Comprehensive Genomic Profiling

Home
Products
Congresses & Events
Comprehensive Genomic Profiling
Sign in
Logout

1 - of results for ""

No results

Are you registered? Register now to view Roche scientific information for HCPs!

Clinical Data

Read more

Tecentriq®
Mechanism of Action
Clinical Data
- Non-small cell lung cancer
Dosing & Administration
AR Management
Resources
- Professional Resources
- Congresses
Safety Information
References
More

You are here:

Products
Tecentriq®
Clinical Data
Non-small cell lung cancer

Clinical Studies

OAK

OAK: the largest Phase III cancer immunotherapy study in previously treated advanced NSCLC, regardless of PD-L1 expression¹

Mechanism of Action

Link

Efficacy

Median OS was 13.8 months with TECENTRIQ vs 9.6 months with docetaxel

Safety

TECENTRIQ showed a favourable safety profile with low toxicity

References:

1. TECENTRIQ prescribing information.

MatCode Approval No.: -1905-V2-3253

Important notice!

This website is intended for the use of healthcare professionals only, Please approve that you are a healthcare professional in order to continue using this website.

Accept Cancel

03.08.2020

Legal Information

Find us on YouTube

Clinical Data

Read more

Clinical Studies

Mechanism of Action